Clinical Trial: A Randomized, Double-blind, Placebo-controlled, Dose-escalating Phase I Clinical Trial

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07585383) titled 'A Randomized, Double-blind, Placebo-controlled, Dose-escalating Phase I Clinical Trial' on May 07.

Brief Summary: This study is aimed to investigate the safety, tolerability and pharmacokinetic characteristics of KR23248 capsule on healthy subjects. This study will be held in China. It will be accepting male and female participants age 18 years to 45 years.

Study Start Date: May 19

Study Type: INTERVENTIONAL

Condition: Schizophrenia

Intervention: DRUG: KR23248

Participants will recieve a single oral dose of KR23248

DRUG: Matching Placebo

Participants will recieve placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Jian...